Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)
Conditions: Kidney Transplant Rejection Interventions: Drug: Conversion to Belatacep; Drug: Standard of care treatment (SOC regimen) with Tacrolimus Sponsors: University Hospital, Rouen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Hospitals | Kidney Transplant | Kidney Transplantation | Prograf | Research | Tacrolimus | Transplant Surgery | Transplants | Urology & Nephrology